EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Uncertainty management in regulatory and health technology assessment decision-making on drugs: guidance of the HTAi-DIA Working Group

Milou Amber Hogervorst iD, Rick Vreman iD, Inkatuuli Heikkinen iD, Indranil Bagchi, Inaki Gutierrez-Ibarluzea iD, Bettina Ryll, Hans-Georg Eichler iD, Elena Petelos iD, Sean Tunis, Claudine Sapede, Wim Goettsch iD, Rosanne Janssens und 11 weitere

International Journal of Technology Assessment in Health Care · 2023 · 39 (1)

DOI: 10.1017/s0266462323000375 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Technology Assessment in Health Care, online erschienen am 16.06.2023. Verfasst von Milou Amber Hogervorst und 22 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht, The Ne…. Hauptthemen laut MEDLINE: Technology Assessment, Biomedical, Policy Making. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Uncertainty is a fundamental component of decision making regarding access to and pricing and reimbursement of drugs. The context-specific interpretation and mitigation of uncertainty remain major challenges for decision makers. Following the 2021 HTAi Global Policy Forum, a cross-sectoral, interdisciplinary HTAi-DIA Working Group (WG) was initiated to develop guidance to support stakeholder deliberation on the systematic identification and mitigation of uncertainties in the regulatory-HTA interface.

Methods

Six online discussions among WG members (Dec 2021–Sep 2022) who examined the output of a scoping review, two literature-based case studies and a survey; application of the initial guidance to a real-world case study; and two international conference panel discussions.

Results

The WG identified key concepts, clustered into twelve building blocks that were collectively perceived to define uncertainty: “unavailable,” “inaccurate,” “conflicting,” “not understandable,” “random variation,” “information,” “prediction,” “impact,” “risk,” “relevance,” “context,” and “judgment.” These were converted into a checklist to explain and define whether any issue constitutes a decision-relevant uncertainty. A taxonomy of domains in which uncertainty may exist within the regulatory-HTA interface was developed to facilitate categorization. The real-world case study was used to demonstrate how the guidance may facilitate deliberation between stakeholders and where additional guidance development may be needed.

Conclusions

The systematic approach taken for the identification of uncertainties in this guidance has the potential to facilitate understanding of uncertainty and its management across different stakeholders involved in drug development and evaluation. This can improve consistency and transparency throughout decision processes. To further support uncertainty management, linkage to suitable mitigation strategies is necessary.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Technology Assessment, BiomedicalPolicy MakingUncertaintyPolicyCosts and Cost Analysis

Stichwörter der Autor:innen

drugshealth technology assessmentregulatory decision makingstakeholder deliberationuncertainty

Autor:innen und Institutionen

  • Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht, The Netherlands.
  • National Health Care Institute (ZIN), Diemen, The Netherlands.
  • Global Regulatory Policy, MSD, Copenhagen, Denmark.
  • Global Pricing & Market Access, GSK, Philadelphia, PA, USA.
  • Basque Foundation for Health Innovation and Research (BIOEF), Barakaldo, Spain.
  • Basque Office for Health Technology Assessment, Osteba, Barakaldo, Spain.

ORCID-Profile: Milou Amber Hogervorst, Rick Vreman, Inkatuuli Heikkinen, Inaki Gutierrez-Ibarluzea, Hans-Georg Eichler, Elena Petelos, Wim Goettsch, Wija Oortwijn

Zitieren

APA

Hogervorst, M. A., Vreman, R., Heikkinen, I., Bagchi, I., Gutierrez-Ibarluzea, I., Ryll, B., Eichler, H. G., Petelos, E., Tunis, S., Sapede, C., Goettsch, W., Janssens, R., Huys, I., Barbier, L., DeJean, D., Strammiello, V., Lingri, D., Goodall, M., Papadaki, M., …, & Oortwijn, W. (2023). Uncertainty management in regulatory and health technology assessment decision-making on drugs: guidance of the HTAi-DIA Working Group. International Journal of Technology Assessment in Health Care, 39(1). https://doi.org/10.1017/s0266462323000375

Vancouver

Hogervorst MA, Vreman R, Heikkinen I, Bagchi I, Gutierrez-Ibarluzea I, Ryll B, et al. Uncertainty management in regulatory and health technology assessment decision-making on drugs: guidance of the HTAi-DIA Working Group. International Journal of Technology Assessment in Health Care. 2023;39(1). doi:10.1017/s0266462323000375

BibTeX
@article{Hogervorst2023,
  author = {Hogervorst, Milou Amber and Vreman, Rick and Heikkinen, Inkatuuli and Bagchi, Indranil and Gutierrez-Ibarluzea, Inaki and Ryll, Bettina and Eichler, Hans-Georg and Petelos, Elena and Tunis, Sean and Sapede, Claudine and Goettsch, Wim and Janssens, Rosanne and Huys, Isabelle and Barbier, Liese and DeJean, Deirdre and Strammiello, Valentina and Lingri, Dimitra and Goodall, Melinda and Papadaki, Magdalini and Toussi, Massoud and Voulgaraki, Despina and Mitan, Ania and Oortwijn, Wija},
  title = {Uncertainty management in regulatory and health technology assessment decision-making on drugs: guidance of the HTAi-DIA Working Group},
  journal = {International Journal of Technology Assessment in Health Care},
  year = {2023},
  volume = {39},
  number = {1},
  doi = {10.1017/s0266462323000375}
}
Kostenlos starten →